TAO Synergies Inc. operates as a biopharmaceutical company currently in the clinical development stage. It is dedicated to advancing a bryostatin-1 therapeutic platform, specifically designed to combat Alzheimer's and various other neurodegenerative and cognitive disorders. Beyond its drug development efforts, the firm is also diversifying its treasury strategy, with a new approach centered on the management of digital assets, primarily focusing on the acquisition and 'staking' of TAO cryptocurrency.